Amisulpride and neuroleptic malignant syndrome

Chang Gung Medical Journal

Volumn 34, Issue 5, 2011, Pages 536-540

  Tu, Ming Che ^a   Hsiao, Cheng Cheng ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Amisulpride; Atypical neuroleptics; Neuroleptic malignant syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; AMISULPRIDE; BROMOCRIPTINE; CLONAZEPAM; CREATINE KINASE; DIPHENHYDRAMINE; MYOGLOBIN; NITROGEN; QUETIAPINE; TRIAZOLAM; UREA;

ADULT; AUDITORY HALLUCINATION; CASE REPORT; CATATONIA; CONSCIOUSNESS DISORDER; DELUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPOREFLEXIA; LABORATORY DIAGNOSIS; LEUKOCYTOSIS; MUSCLE RIGIDITY; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; NYSTAGMUS; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; TACHYCARDIA; UREA NITROGEN BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; SULPIRIDE;

EID: 80055088378     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Abidi S, Bhaskara SM. From chlorpromazine to clozapine--antipsychotic adverse effects and the clinician's dilemma. Can J Psychiatry 2003;48:749-55.
2. Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000;30:314-21.
3. Abay E, Kose R. Amisulpride-induced neuroleptic maligant syndrome. J Neuropsychiatry Clin Neurosci 2007;19:488-9.
4. Atbasoglu EC, Ozguven HD, Can Saka M, Goker C. Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. J Clin Psychiatry 2004;65;1724-5.
5. Peritogiannis V, Tsouli S, Pappas D, Mavreas V, Konitsiotis S. Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. Clin Neuropharmacol 2007;30:245-6.
6. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-45.
7. Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf 1998;19:73-82.
8. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129-35.
9. Green B. Focus on amisulpride. Curr Med Res Opin 2002;18:113-7.
10. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Press, 2000.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
13. Park-Matsumoto YC, Tazawa T. Neuroleptic malignant syndrome associated with diphenhydramine and diprophyllin overdose in a depressed patient. J Neurol Sci 1999;162:108-9.
14. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
15. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989;146:717-25.
16. Berardi D, Amore M, Keck PE Jr, Troia M, Dell'Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998;44:748-54.
17. Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharm 1984;3:302-7.
18. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. Can Med Asso J 2003;169:439-42.